Provided is a heterocyclic compound of Chemical Formula 1:

##STR00001## a is a substituted or unsubstituted tetracyclic or higher aromatic or heteroaromatic ring, and b is a benzene or naphthalene ring; at least two of G1 to G3 are a group of Chemical Formula A, and any remaining group, and G101, is hydrogen, deuterium, halogen, cyano, nitro, or a substituted or unsubstituted: silyl, boron, alkyl, alkoxy, cycloalkyl, aryl, or heteroaryl group;

##STR00002## L1 and L2 are a direct bond, or a substituted or unsubstituted arylene or heteroarylene group; Ar1 and Ar2 are hydrogen, deuterium, halogen, cyano, nitro, or a substituted or unsubstituted: silyl, boron, alkyl, alkoxy, cycloalkyl, aryl, or a heteroaryl group, or a fused ring group of an aromatic hydrocarbon ring and aliphatic hydrocarbon ring, or bond to each other to form a substituted or unsubstituted heteroring; and an organic light emitting device including the same.

Provided is a heterocyclic compound of Chemical Formula 1:

##STR00001## a is a substituted or unsubstituted tetracyclic or higher aromatic or heteroaromatic ring, and b is a benzene or naphthalene ring; at least two of G1 to G3 are a group of Chemical Formula A, and any remaining group, and G101, is hydrogen, deuterium, halogen, cyano, nitro, or a substituted or unsubstituted: silyl, boron, alkyl, alkoxy, cycloalkyl, aryl, or heteroaryl group;

##STR00002## L1 and L2 are a direct bond, or a substituted or unsubstituted arylene or heteroarylene group; Ar1 and Ar2 are hydrogen, deuterium, halogen, cyano, nitro, or a substituted or unsubstituted: silyl, boron, alkyl, alkoxy, cycloalkyl, aryl, or a heteroaryl group, or a fused ring group of an aromatic hydrocarbon ring and aliphatic hydrocarbon ring, or bond to each other to form a substituted or unsubstituted heteroring; and an organic light emitting device including the same.

The present disclosure provides for compounds of Formula (I)

##STR00001##

wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

The present disclosure provides for compounds of Formula (I)

##STR00001##

wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.

The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.

The present disclosure provides for compounds of Formula (I)

##STR00001##

wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

The present disclosure provides for compounds of Formula (I)

##STR00001##

wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.

##STR00001##

Novel 9 membered ring carbazole compounds are disclosed, which can be used as host materials etc. in an electroluminescent device. Compared with the existing host materials etc., these novel compounds can effectively modulate the charge transporting properties in the above materials and give OLEDs better performance. Also disclosed are an electroluminescent device and a formulation.